Literature DB >> 25047947

Factors affecting receipt of expensive cancer treatments and mortality: evidence from stem cell transplantation for leukemia and lymphoma.

Jean M Mitchell1, Elizabeth A Conklin.   

Abstract

OBJECTIVE: To identify factors that affect whether patients diagnosed with either leukemia or lymphoma receive a stem cell transplant and secondly if receipt of stem cell transplantation is linked to improved survival. DATA: California inpatient discharge records (2002-2003) for patients with either leukemia or lymphoma linked with vital statistics death records (2002-2005). STUDY
DESIGN: Bivariate Probit treatment effects model that accounts for both the type of treatment received and survival while controlling for nonrandom selection due to unobservable factors. PRINCIPAL
FINDINGS: Having private insurance coverage and residence in a well-educated county increased the chances a patient with either disease received HSCT. Increasing age and travel distance to the nearest transplant hospital had the opposite effect. Receipt of HSCT had a significant impact on mortality. We found the probability of death was 4.3 percentage points higher for leukemia patients who did NOT have HSCT. Receipt of HSCT reduced the chances of dying by almost 50 percent. The likelihood of death among lymphoma patients who underwent HSCT was almost 5 percentage points lower, a 70 percent reduction in the probability of death.
CONCLUSIONS: The findings raise concern about access to expensive, but highly effective cancer treatments for patients with certain hematologic malignancies. © Health Research and Educational Trust.

Entities:  

Keywords:  Leukemia; access; bivariate probit; insurance; lymphoma; stem cell transplantation; survival

Mesh:

Year:  2014        PMID: 25047947      PMCID: PMC4319878          DOI: 10.1111/1475-6773.12208

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  16 in total

Review 1.  Hematopoietic stem cell transplantation in Hodgkin disease.

Authors:  Donna E Reece
Journal:  Curr Opin Oncol       Date:  2002-03       Impact factor: 3.645

2.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

3.  Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors.

Authors:  J M Mitchell; K R Meehan; J Kong; K A Schulman
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

4.  High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices.

Authors:  S J Horning; N J Chao; R S Negrin; R T Hoppe; G D Long; W W Hu; R M Wong; B W Brown; K G Blume
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

5.  Hematopoietic stem cell transplantation among patients with leukemia of all ages in Texas.

Authors:  Jessica P Hwang; Tony P Lam; Deborah S Cohen; Michele L Donato; Jane M Geraci
Journal:  Cancer       Date:  2004-11-15       Impact factor: 6.860

6.  Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada.

Authors:  Derek S Serna; Stephanie J Lee; Mei-jie Zhang; k Scott Baker; Mary Eapen; Mary M Horowitz; John P Klein; J Douglas Rizzo; Fausto R Loberiza
Journal:  J Clin Oncol       Date:  2003-10-15       Impact factor: 44.544

Review 7.  Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature.

Authors:  K R Meehan; R S Pritchard; J W Leichter; B Littenberg; H G Welch
Journal:  Am J Hematol       Date:  1995-10       Impact factor: 10.047

8.  Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables.

Authors:  M McClellan; B J McNeil; J P Newhouse
Journal:  JAMA       Date:  1994-09-21       Impact factor: 56.272

9.  Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia.

Authors:  L M Poon; R Bassett; G Rondon; A Hamdi; M Qazilbash; C Hosing; R B Jones; E J Shpall; U R Popat; Y Nieto; L L Worth; L Cooper; M De Lima; R E Champlin; P Kebriaei
Journal:  Bone Marrow Transplant       Date:  2012-10-22       Impact factor: 5.483

Review 10.  Role of autologous stem cell transplantation in chronic lymphocytic leukemia.

Authors:  Vassiliki Rizouli; John G Gribben
Journal:  Curr Opin Hematol       Date:  2003-07       Impact factor: 3.284

View more
  10 in total

1.  Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  J R Passweg; H Baldomero; P Bader; C Bonini; S Cesaro; P Dreger; R F Duarte; C Dufour; J Kuball; D Farge-Bancel; A Gennery; N Kröger; F Lanza; A Nagler; A Sureda; M Mohty
Journal:  Bone Marrow Transplant       Date:  2016-11-07       Impact factor: 5.483

Review 2.  Predispositions to Lymphoma: A Practical Review for Genetic Counselors.

Authors:  Morgan Similuk; V Koneti Rao; Jane Churpek; Michael Lenardo
Journal:  J Genet Couns       Date:  2016-06-06       Impact factor: 2.537

3.  Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.

Authors:  S Hong; L Rybicki; D M Abounader; B J Bolwell; R Dean; A T Gerds; B K Hamilton; B T Hill; D Jagadeesh; M Kalaycio; H D Liu; B Pohlman; R Sobecks; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2016-04-25       Impact factor: 5.483

4.  Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma.

Authors:  Kira Bona; Yimei Li; Lena E Winestone; Kelly D Getz; Yuan-Shung Huang; Brian T Fisher; Ami V Desai; Troy Richardson; Matt Hall; Arlene Naranjo; Tara O Henderson; Richard Aplenc; Rochelle Bagatell
Journal:  J Natl Cancer Inst       Date:  2021-03-01       Impact factor: 11.816

5.  Utilisation and outcomes of allogeneic hematopoietic cell transplantation in Ontario, Canada, and New York State, USA: a population-based retrospective cohort study.

Authors:  Samantha Aliza Hershenfeld; John Matelski; Vicki Ling; Michael Paterson; Matthew Cheung; Peter Cram
Journal:  BMJ Open       Date:  2020-10-31       Impact factor: 2.692

6.  Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States.

Authors:  John L Vaughn; Orysya Soroka; Narendranath Epperla; Monika Safford; Laura C Pinheiro
Journal:  Cancer Med       Date:  2021-09-01       Impact factor: 4.452

7.  Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.

Authors:  Sanghee Hong; Ruta Brazauskas; Kyle M Hebert; Siddhartha Ganguly; Hisham Abdel-Azim; Miguel Angel Diaz; Sara Beattie; Stefan O Ciurea; David Szwajcer; Sherif M Badawy; Alois A Gratwohl; Charles LeMaistre; Mahmoud D S M Aljurf; Richard F Olsson; Neel S Bhatt; Nosha Farhadfar; Jean A Yared; Ayami Yoshimi; Sachiko Seo; Usama Gergis; Amer M Beitinjaneh; Akshay Sharma; Hillard Lazarus; Jason Law; Matthew Ulrickson; Hasan Hashem; Hélène Schoemans; Jan Cerny; David Rizzieri; Bipin N Savani; Rammurti T Kamble; Bronwen E Shaw; Nandita Khera; William A Wood; Shahrukh Hashmi; Theresa Hahn; Stephanie J Lee; J Douglas Rizzo; Navneet S Majhail; Wael Saber
Journal:  Cancer       Date:  2020-10-21       Impact factor: 6.860

8.  Barriers to Access to Hematopoietic Cell Transplantation among Patients with Acute Myeloid Leukemia in Virginia.

Authors:  Joseph Mock; Christa Meyer; Lih-Wen Mau; Cecilia Nguyen; Puja Arora; Courtney Heron; Rajesh Balkrishnan; Linda Burns; Steven Devine; Karen Ballen
Journal:  Transplant Cell Ther       Date:  2021-07-02

9.  Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.

Authors:  Colin Flannelly; Bryan E-Xin Tan; Jian Liang Tan; Colin M McHugh; Chandrika Sanapala; Tara Lagu; Jane L Liesveld; Omar Aljitawi; Michael W Becker; Jason H Mendler; Heidi D Klepin; Wendy Stock; Tanya M Wildes; Andrew Artz; Navneet S Majhail; Kah Poh Loh
Journal:  Biol Blood Marrow Transplant       Date:  2020-09-20       Impact factor: 5.609

10.  Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis.

Authors:  Kira Bona; Ruta Brazauskas; Naya He; Leslie Lehmann; Hisham Abdel-Azim; Ibrahim A Ahmed; A Samer Al-Homsi; Mahmoud Aljurf; Staci D Arnold; Sherif M Badawy; Minoo Battiwalla; Sara Beattie; Neel S Bhatt; Jignesh Dalal; Christopher E Dandoy; Miguel Angel Diaz; Haydar A Frangoul; César O Freytes; Siddhartha Ganguly; Biju George; David Gomez-Almaguer; Theresa Hahn; Rammurti T Kamble; Jennifer M Knight; C Fred LeMaistre; Jason Law; Hillard M Lazarus; Navneet S Majhail; Richard F Olsson; Jaime Preussler; Bipin N Savani; Raquel Schears; Sachiko Seo; Akshay Sharma; Alok Srivastava; Amir Steinberg; David Szwajcer; Baldeep Wirk; Ayami Yoshimi; Nandita Khera; William A Wood; Shahrukh Hashmi; Christine N Duncan; Wael Saber
Journal:  Blood       Date:  2021-01-28       Impact factor: 25.476

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.